(ELV) Elevance Health - Overview
Stock: Health Insurance, Pharmacy Services, Specialty Care, Administrative Services
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.95% |
| Yield on Cost 5y | 3.18% |
| Yield CAGR 5y | 10.91% |
| Payout Consistency | 100.0% |
| Payout Ratio | 20.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.2% |
| Relative Tail Risk | -7.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.21 |
| Alpha | -20.48 |
| Character TTM | |
|---|---|
| Beta | 0.200 |
| Beta Downside | 0.227 |
| Drawdowns 3y | |
|---|---|
| Max DD | 50.38% |
| CAGR/Max DD | -0.21 |
Description: ELV Elevance Health January 29, 2026
Elevance Health Inc. (NYSE: ELV) is a U.S. health-benefits company organized into four operating segments-Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It delivers a full spectrum of health plans (individual, employer-group, Medicare, Medicaid, and Federal Employee Program) and ancillary products such as stop-loss, dental, vision, and supplemental insurance, while also operating a large pharmacy-services business that includes home-delivery, specialty pharmacy, formulary management, and infusion services. The firm’s technology platform, HealthOS, supports utilization management, virtual care, payment-integrity, data analytics, and post-acute care coordination, and its brands include Anthem Blue Cross & Blue Shield, Wellpoint, and Carelon.
Key recent metrics (Q4 2024 / FY 2024):
• Total revenue ≈ $152 billion, up 5 % YoY, driven by a 7 % rise in pharmacy-services revenue and continued growth in Medicare Advantage enrollment (≈ 6 % YoY).
• Membership base ≈ 115 million lives, with employer-group coverage stable and Medicaid enrollment expanding in several states following recent policy extensions.
• Adjusted EPS $4.85, net income $1.2 billion, with an operating margin of 4.5 % after integrating the Carelon acquisitions.
Sector drivers include an aging U.S. population (projected 10 % increase in Medicare-eligible adults by 2030), sustained inflation in medical-service prices (≈ 4 % annual CPI for health care), and consolidation trends in the pharmacy-benefit-management market that favor large, integrated insurers.
For a deeper, data-rich dive into Elevance’s valuation dynamics, you may find ValueRay’s analytical tools worth exploring.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 5.66b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 2.36 > 1.0 |
| NWC/Revenue: 11.06% < 20% (prev 11.32%; Δ -0.26% < -1%) |
| CFO/TA 0.04 > 3% & CFO 4.91b > Net Income 5.66b |
| Net Debt (-8.24b) to EBITDA (9.57b): -0.86 < 3 |
| Current Ratio: 1.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (221.8m) vs 12m ago -4.02% < -2% |
| Gross Margin: 32.51% > 18% (prev 0.43%; Δ 3208 % > 0.5%) |
| Asset Turnover: 166.7% > 50% (prev 151.3%; Δ 15.43% > 0%) |
| Interest Coverage Ratio: 5.73 > 6 (EBITDA TTM 9.57b / Interest Expense TTM 1.40b) |
Altman Z'' 3.19
| A: 0.18 (Total Current Assets 63.00b - Total Current Liabilities 41.03b) / Total Assets 121.49b |
| B: 0.29 (Retained Earnings 35.59b / Total Assets 121.49b) |
| C: 0.07 (EBIT TTM 8.03b / Avg Total Assets 119.19b) |
| D: 0.57 (Book Value of Equity 43.88b / Total Liabilities 77.47b) |
| Altman-Z'' Score: 3.19 = A |
What is the price of ELV shares?
Over the past week, the price has changed by -1.96%, over one month by -8.72%, over three months by +8.36% and over the past year by -11.51%.
Is ELV a buy, sell or hold?
- StrongBuy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ELV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 392.7 | 15.8% |
| Analysts Target Price | 392.7 | 15.8% |
| ValueRay Target Price | 342.9 | 1.2% |
ELV Fundamental Data Overview January 31, 2026
P/E Forward = 12.6103
P/S = 0.3895
P/B = 1.7573
P/EG = 1.3008
Revenue TTM = 198.69b USD
EBIT TTM = 8.03b USD
EBITDA TTM = 9.57b USD
Long Term Debt = 31.17b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.25b USD (from shortTermDebt, last quarter)
Debt = 1.25b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -8.24b USD (from netDebt column, last quarter)
Enterprise Value = 69.32b USD (77.56b + Debt 1.25b - CCE 9.49b)
Interest Coverage Ratio = 5.73 (Ebit TTM 8.03b / Interest Expense TTM 1.40b)
EV/FCF = 18.40x (Enterprise Value 69.32b / FCF TTM 3.77b)
FCF Yield = 5.43% (FCF TTM 3.77b / Enterprise Value 69.32b)
FCF Margin = 1.90% (FCF TTM 3.77b / Revenue TTM 198.69b)
Net Margin = 2.85% (Net Income TTM 5.66b / Revenue TTM 198.69b)
Gross Margin = 32.51% ((Revenue TTM 198.69b - Cost of Revenue TTM 134.09b) / Revenue TTM)
Gross Margin QoQ = 11.61% (prev 14.18%)
Tobins Q-Ratio = 0.57 (Enterprise Value 69.32b / Total Assets 121.49b)
Interest Expense / Debt = 29.30% (Interest Expense 366.0m / Debt 1.25b)
Taxrate = 15.63% (1.05b / 6.71b)
NOPAT = 6.77b (EBIT 8.03b * (1 - 15.63%))
Current Ratio = 1.54 (Total Current Assets 63.00b / Total Current Liabilities 41.03b)
Debt / Equity = 0.03 (Debt 1.25b / totalStockholderEquity, last quarter 43.88b)
Debt / EBITDA = -0.86 (Net Debt -8.24b / EBITDA 9.57b)
Debt / FCF = -2.19 (Net Debt -8.24b / FCF TTM 3.77b)
Total Stockholder Equity = 43.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.75% (Net Income 5.66b / Total Assets 121.49b)
RoE = 13.01% (Net Income TTM 5.66b / Total Stockholder Equity 43.52b)
RoCE = 10.75% (EBIT 8.03b / Capital Employed (Equity 43.52b + L.T.Debt 31.17b))
RoIC = 9.13% (NOPAT 6.77b / Invested Capital 74.16b)
WACC = 6.94% (E(77.56b)/V(78.81b) * Re(6.65%) + D(1.25b)/V(78.81b) * Rd(29.30%) * (1-Tc(0.16)))
Discount Rate = 6.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.01%
[DCF Debug] Terminal Value 81.83% ; FCFF base≈2.61b ; Y1≈2.54b ; Y5≈2.56b
Fair Price DCF = 293.8 (EV 57.06b - Net Debt -8.24b = Equity 65.30b / Shares 222.2m; r=6.94% [WACC]; 5y FCF grow -3.53% → 2.90% )
EPS Correlation: -31.46 | EPS CAGR: -21.49% | SUE: 0.36 | # QB: 0
Revenue Correlation: 95.99 | Revenue CAGR: 7.12% | SUE: 1.16 | # QB: 6
EPS next Quarter (2026-03-31): EPS=10.47 | Chg30d=+0.086 | Revisions Net=-1 | Analysts=14
EPS current Year (2026-12-31): EPS=26.11 | Chg30d=-0.745 | Revisions Net=+0 | Growth EPS=-13.8% | Growth Revenue=+0.9%
EPS next Year (2027-12-31): EPS=30.06 | Chg30d=-1.121 | Revisions Net=+0 | Growth EPS=+15.1% | Growth Revenue=+3.0%